

Flt-3L

Catalog # PVGS1391

Product Information

Primary Accession Species	P49772 Mouse
Sequence	Gly27-Arg188
Purity	> 95% as analyzed by SDS-PAGE
Endotoxin Level	
Biological Activity	ED ₅₀
Expression System	CHO
Formulation	Lyophilized after extensive dialysis against PBS.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O or PBS up to 100 µg/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Additional Information

Gene ID	14256
Other Names	Fms-related tyrosine kinase 3 ligand, Flt3 ligand, Flt3L, SL cytokine, Flt3lg, Flt3l
Target Background	Flt3L, also known as Fms-related tyrosine kinase 3 ligand and SL cytokine, is a single-pass type I membrane protein. It is expressed by stromal cells and T cells. Flt3L signals through tyrosine kinase receptor Flt3/Flk2 to stimulate the proliferation of early hematopoietic progenitor cells. It synergizes with other growth factors, such as GM-CSF, IL-3 and CSF, to promote the differentiation of both myeloid and lymphoid cells. Alternative splicing and proteolytic cleavage of membrane-bound Flt3L generates a soluble extracellular domain (ECD) isoform with full biological activity.

Protein Information

Name	Flt3lg
Synonyms	Flt3l

Function	Stimulates the proliferation of early hematopoietic cells by activating FLT3. Synergizes well with a number of other colony stimulating factors and interleukins. Essential for the development of natural killer (NK) cells, B cells, and dendritic cells (DCs).
Cellular Location	Cell membrane; Single-pass type I membrane protein [Isoform 4]: Secreted. Note=Inactive.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.